Author Archives: Jeb Keiper

By Jeb Keiper, CEO of Nimbus Therapeutics, as part of the From The Trenches feature of LifeSciVC. @JebKeiper Earlier this year, Nimbus closed the sale of our allosteric TYK2 program, which was acquired by Takeda for $4 billion upfront. To

By Jeb Keiper, CEO of Nimbus Therapeutics, as part of the From The Trenches feature of LifeSciVC Forward Nimbus Therapeutics began 14 years ago.  The premise at the time was that putting computational chemistry in the primary position for new

Family Oddball, and a New Class of Safe Oral Autoimmune & Inflammatory Disease Treatment with Blockbuster Potential By Jeb Keiper, CEO of Nimbus Therapeutics, as part of the From The Trenches feature of LifeSciVC. On day one of the JPM

By Jeb Keiper, CEO of Nimbus Therapeutics, as part of the From The Trenches feature of LifeSciVC. This blog is dedicated to the front-line healthcare workers, essential service workers, scientists, patients, and their families who confront COVID-19 every day, and

This blog was written by Jeb Keiper, CEO of Nimbus Therapeutics LLC, as part of the From The Trenches feature of LifeSciVC. Like many middle-aged weekend warriors, I’ve been recently sidelined by injury simply through doing what I’ve regularly done:

This blog was written by Jeb Keiper, CEO of Nimbus Therapeutics LLC, as part of the From The Trenches feature of LifeSciVC. It is with great excitement that we at Nimbus are ringing in our 10th birthday this month. It’s

This blog was written by Jeb Keiper, CFO & CBO of Nimbus Therapeutics LLC, as part of the From The Trenches feature of LifeSciVC. Elon Musk has a flare for the dramatic, shocking Wall Street (and others) the first week

This blog was written by Jeb Keiper, CFO & CBO of Nimbus Therapeutics LLC, as part of the From The Trenches feature of LifeSciVC. A fresh Q1 is underway, your meetings at JPMorgan were top notch, and you have a

This blog was written by Jeb Keiper, CBO of Nimbus Therapeutics LLC, as part of the From The Trenches feature of LifeSciVC. Walking the streets of Union Square in mid-January torrential rain, we had the good fortune of sharing the

This blog was written by Jeb Keiper, CBO of Nimbus Therapeutics LLC, as part of the From The Trenches feature of LifeSciVC. Unsurprisingly, I had not given that much thought to the parent entity of my new employer when I